PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
University of the Witwatersrand · Louisville Metabolic and Atherosclerosis Research Center · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
746
total citations
- FWCI
- 91.64
- Percentile
- 100%
- References
- 34
Citations per year
Authors
18- FJFrederick J. RaalCorresponding
University of the Witwatersrand
- EAEvan A. Stein
Louisville Metabolic and Atherosclerosis Research Center
- RDRobert Dufour
Université de Montréal, Montreal Clinical Research Institute
- TTTraci Turner
Louisville Metabolic and Atherosclerosis Research Center
- FCFernando Civeira
Hospital Universitario Miguel Servet
Topics & keywords
Topics
Keywords
- Evolocumab
- Ezetimibe
- Medicine
- Placebo
- PCSK9
- Familial hypercholesterolemia
- Cholesterol
- Statin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.